Laura Prendergast
Stock Analyst at Stifel
(3.67)
# 766
Out of 5,126 analysts
15
Total ratings
57.14%
Success rate
63.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $85 → $170 | $97.49 | +74.38% | 4 | Jan 22, 2026 | |
| TNGX Tango Therapeutics | Initiates: Buy | $15 | $12.51 | +19.90% | 1 | Dec 4, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $5.68 | +111.27% | 1 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $103.59 | +30.32% | 2 | Nov 17, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $2.26 | +254.77% | 2 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $12.29 | -67.45% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $37.08 | -56.85% | 1 | Oct 16, 2025 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.02 | +692.08% | 2 | Aug 14, 2024 |
Revolution Medicines
Jan 22, 2026
Maintains: Buy
Price Target: $85 → $170
Current: $97.49
Upside: +74.38%
Tango Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $15
Current: $12.51
Upside: +19.90%
Foghorn Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $12
Current: $5.68
Upside: +111.27%
Nuvalent
Nov 17, 2025
Maintains: Buy
Price Target: $115 → $135
Current: $103.59
Upside: +30.32%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $2.26
Upside: +254.77%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $12.29
Upside: -67.45%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $37.08
Upside: -56.85%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.02
Upside: +692.08%